Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT04577326 · ClinicalTrials.gov registry record · Phase 1
Mesothelin-targeted CAR T-cell Therapy in Patients With Mesothelioma
A Phase 1 study of Malignant Pleural Mesothelioma (MPM), sponsored by Memorial Sloan Kettering Cancer Center.
- Active
- Registry status
- Phase 1
- Development phase
- 14
- Enrollment target
- 1
- Study location
NCT04577326: Active Phase 1 study of Malignant Pleural Mesothelioma (MPM), sponsored by Memorial Sloan Kettering Cancer Center.
NCT04577326 is a Phase 1 study of Malignant Pleural Mesothelioma (MPM) that is active but no longer recruiting, run by Memorial Sloan Kettering Cancer Center. The registered enrollment target is 14 participants, below the 60-participant average among 29,502 other Phase 1 trials with a reported enrollment target (77% lower). The trial reports 1 study location across 1 state. According to ClinicalTrials.gov, the official US trial registry.
The verdict
NCT04577326, a Phase 1 study of Malignant Pleural Mesothelioma (MPM), is active but no longer recruiting, sponsored by Memorial Sloan Kettering Cancer Center.
- ACTIVE NOT RECRUITING
- Registry status
- Phase 1
- Development phase
- 14 participants
- Enrollment target
- 1
- Study location
Study Summary
This study will test the safety of MSLN-targeted CAR-T cells at different doses to find the safest dose to give to people with MPM. The researchers want to see what effects, if any, the study treatment has on people with this type of cancer. This study is the first time that an MSLN-targeted CAR-T cell treatment with an anti-PD1 component is being given to people.
Primary Outcome
CTCAE v5.0 will be used to assess the severity of all treatment emerging toxicities/adverse events regardless
Conditions Studied
Interventions
- DRUG cyclophosphamide
- BIOLOGICAL CAR T cells
Study Locations (1)
New York
- Memorial Sloan Kettering Cancer Center (All Protocol Activities) - New York
Trial Details
| Field | Value |
|---|---|
| Enrollment Target | 14 participants |
| Start Date | 2020-09-30 |
| Est. Completion | 2026-09-30 |
| Phase | Phase 1 |
What the registry record for NCT04577326 still lists
NCT04577326 is an interventional study that assigns participants to a tested intervention. The registry caps enrollment at 14 participants, a relatively small participant target, below the 60-participant average among 29,502 other Phase 1 trials with a reported enrollment target (77% lower).
The record links to 1 condition, with Malignant Pleural Mesothelioma (MPM) appearing as the primary indexed condition, and to 2 interventions - of which cyclophosphamide is the first listed.
NCT04577326 reports a single indexed study location in New York.
Frequently Asked Questions
What is clinical trial NCT04577326 about?
NCT04577326 is a clinical study titled "Mesothelin-targeted CAR T-cell Therapy in Patients With Mesothelioma". This study will test the safety of MSLN-targeted CAR-T cells at different doses to find the safest dose to give to people with MPM. The researchers want to see what effects, if any, the study treatment has on people with this type of cancer. This study is the first time that an MSLN-targeted CAR-T c...
What is the current status of trial NCT04577326?
This trial is currently active not recruiting. It is a Phase 1 study. The enrollment target is 14 participants. The study started on 2020-09-30. Estimated completion is 2026-09-30.
What conditions does trial NCT04577326 study?
This clinical trial studies the following conditions: Malignant Pleural Mesothelioma (MPM).
What interventions are being tested in trial NCT04577326?
The interventions under investigation include: cyclophosphamide (DRUG), CAR T cells (BIOLOGICAL).
Who is sponsoring clinical trial NCT04577326?
This trial is sponsored by Memorial Sloan Kettering Cancer Center, which has 1,884 total clinical trials registered on ClinicalTrials.gov.
Where is trial NCT04577326 being conducted?
This trial has 1 study location across New York. Contact the study sites directly through ClinicalTrials.gov for enrollment availability.
Learn More About Clinical Trials
Similar trials for Malignant Pleural Mesothelioma (MPM)
Matched on the same primary condition, ranked to surface studies in the same phase first, then by recruiting status, no relevance scoring or editorial curation.
Where NCT04577326's enrollment target sits among peer trials
14 1844th of 2000 higher than 154 of 2,000 other Phase 1 trials
participants (enrollment target), bucketed by value
Each bar is a band; taller bars hold more other Phase 1 trials. The dashed line + filled bar mark this entry. Hover or tap any bar for its full count and share, and where it sits relative to this entry.
Source ClinicalTrials.gov registry export · 2026-08-08
Nationwide trials with similar profiles
Cross-condition peers matched on enrollment target and registry start date, not the same-condition list above.
Similar enrollment target
- NCT02523092 · 14 participants · Phase 4
Use of CXCL9 as a Biomarker of Acthar Efficacy
- NCT04263285 · 14 participants · NA
Treatment of Depression Post-SCI
- NCT04743271 · 14 participants · NA
Food and Circadian Timing
- NCT05065671 · 14 participants · Phase 1
Microbiome Derived Metabolism and Pharmacokinetics
Similar registry start date
- NCT05962346 · started 2026-12 · NA
Fetal Endoscopic Tracheal Occlusion for Congenital Diaphragmatic Hernia
- NCT07125183 · started 2026-12 · Phase 2
Study on Efficacy and Tolerability of Weekly Doxorubicin in Elderly Patients With Advanced or Metastatic Leiomyosarcoma
- NCT07292298 · started 2026-11 · Phase 2
Phase 2 Single-Arm Rectal Cancer Brachytherapy for Patients With Low-Lying Residual Adenocarcinoma After Total Neoadjuvant Therapy to Improve Organ Preservation Rates
- NCT06358040 · started 2026-10 · NA
Opioid Dispenser for Microdiscectomy/Laminectomy